AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25326180
Drug: Standard non-surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard non-surgical therapy + tNMR (Treatment Group)
Trial: 19239400
Drug: Injection diclofenac
RxNorm normalized name: diclofenac Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection diclofenac sodium 75 mg/ml (test formulation) given as an intradeltoid injection
Trial: 19239400
Drug: Injection diclofenac
RxNorm normalized name: diclofenac Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection diclofenac sodium 75 mg/3 ml (reference formulation) given intragluteally
Trial: 16439873
Drug: 180 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180 mg enfuvirtide, once-daily (QD)
Trial: 16439873
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg enfuvirtide, twice-daily (BID)
Trial: 12616182
Drug: Granisetron pretreatment
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron pretreatment (5 mL of 2 mg in 0.9% saline)
Trial: 12616182
Drug: Lidocaine pretreatment
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine pretreatment (5 mL of 40 mg in 0.9% saline)
Trial: 12616182
Drug: Saline pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline pretreatment (5 mL of 0.9% saline)
Trial: 1474160
Drug: Fasted state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted state (30-mg OSR tablet every 12 hours)
Trial: 1474160
Drug: Fed state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed state (30-mg OSR tablet every 12 hours)
Trial: 6386008
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (GBE) (40 mg GBE; rökan)
Trial: 30559051
Drug: Lenalidomide maintenance
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide maintenance (10 mg orally on days 1–21 of a 28‐day cycle)
Trial: 26581327
Drug: Delafloxacin 50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 50, 100, 200, 400, 800, 1200, and 1600 mg (single ascending-dose study)
Trial: 26581327
Drug: Delafloxacin 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 250 mg (single-dose crossover study)
Trial: 26581327
Drug: Delafloxacin 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 250 mg (parallel group study)
Trial: 26581327
Drug: Delafloxacin 100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 100, 200, 400, 800, 1200 mg once daily for 5 days (multiple ascending-dose study)
Trial: 26581327
Drug: Delafloxacin 900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delafloxacin 900 mg (single-dose, randomized, 3-period crossover study)
Trial: 19208560
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin plus aspirin (LMWH/ASA)
Trial: 9723147
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg per day)
Trial: 8039533
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of omeprazole and doxycycline monohydrate
Trial: 28576901
Drug: Ultrasound-guided popliteal
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided popliteal sciatic (20 mL) and saphenal nerve (8 mL) PNB with ropivacaine 7.5 mg/mL
Trial: 28576901
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia (2 mL) with hyperbaric bupivacaine 5 mg/mL
Trial: 23917335
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration therapy with 2.5 % carbohydrate beverage (group A)
Trial: 1827006
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg isradipine twice daily
Trial: 8466715
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg nifedipine retard once daily
Trial: 28734623
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Clopidogrel (n=56)
Trial: 28734623
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Placebo (n=57)
Trial: 19113922
Drug: Phylloquinone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phylloquinone (1 mg daily)
Trial: 19113922
Drug: MK4 (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK4 (45 mg daily)
Trial: 12544375
Drug: Reboxetine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (8 to 10 mg/d)
Trial: 9100582
Drug: Cyclic recombinant
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic recombinant human growth hormone (20 micrograms/kg.day) plus salmon calcitonin (100 U/day)
Trial: 9100582
Drug: Cyclic recombinant
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic recombinant human growth hormone (20 micrograms/kg.day) plus placebo
Trial: 9100582
Drug: Cyclic recombinant
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic recombinant human growth hormone plus placebo
Trial: 9100582
Drug: Cyclic recombinant
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic recombinant human growth hormone plus salmon calcitonin
Trial: 8386794
Drug: Lomefloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin (400 mg orally 2‐6 h before surgery)
Trial: 8386794
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g intravenously 30‐90 min before surgery)
Trial: 2948534
Drug: AH23848 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH23848 (70 mg orally)
Trial: 2948534
Drug: AH23848 (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AH23848 (70 mg three times a day for seven days)
Trial: 29911511
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) sessions, three interviews per subject, performed monthly over a 3-month period
Trial: 20863951
Drug: varespladib 500
RxNorm normalized name: Varespladib
DrugBank: Varespladib (DB11909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: varespladib 500 mg daily plus atorvastatin 80 mg daily
Trial: 20863951
Drug: placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo plus atorvastatin 80 mg daily
Trial: 18226046
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (OGTT) at baseline and after 6 years
Trial: 18226046
Drug: Weight increase,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight increase, waist-to-hip ratio, indices of insulin resistance and beta-cell function
Trial: 10484538
Drug: Beta-radiation therapy
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-radiation therapy after balloon angioplasty
Trial: 1860132
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac (50 mg to 100 mg)
Trial: 6311477
Drug: Enalapril (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10, 20, or 40 mg/day for 4 wk each)
Trial: 27491531
Drug: Guided internet
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided internet cognitive-behavioural therapy (ICBT)
Trial: 27491531
Drug: Unguided internet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided internet cognitive-behavioural therapy (U-ICBT)
Trial: 17564637
Drug: efalizumab 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efalizumab 0.5 mg/kg weekly subcutaneously for 12 weeks
Trial: 17564637
Drug: efalizumab 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efalizumab 2 mg/kg weekly subcutaneously for 12 weeks
Trial: 17564637
Drug: efalizumab (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efalizumab (both doses)
Trial: 17564637
Drug: efalizumab (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: efalizumab (higher dose)
Trial: 14643816
Drug: Diazoxide (DZX)
DrugBank: Diazoxide (DB01119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diazoxide (DZX) group, 1.5 mg/kg diazoxide infused intravenously within 5 min followed by a 5‐min washout before CPB.
Trial: 14643816
Drug: Control group,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group, time‐matched period of placebo infusion.
Trial: 8910173
Drug: Direct obturator
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct obturator nerve block with 15 ml of lidocaine (Group A, n = 20)
Trial: 8910173
Drug: Bilateral direct
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral direct obturator nerve block with 30 ml of lidocaine (Group B, n = 12)
Trial: 8910173
Drug: 3‐in‐1 indirect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐in‐1 indirect obturator nerve block with 40 ml of lidocaine (Group C, n = 17)
Trial: 7104161
Drug: Oral meptazinol
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meptazinol (50 mg)
Trial: 7104161
Drug: Oral meptazinol
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meptazinol (100 mg)
Trial: 7104161
Drug: Oral meptazinol
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meptazinol (150 mg)
Trial: 7104161
Drug: Oral meptazinol
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral meptazinol (200 mg)
Trial: 25885012
Drug: Psychostimulant plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychostimulant plus parent training plus placebo (basic treatment)
Trial: 25885012
Drug: Psychostimulant plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychostimulant plus parent training plus risperidone (augmented treatment)
Trial: 24035403
Drug: LY2140023 (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2140023 (20mg twice daily)
Trial: 21926861
Drug: Protocol B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol B (80 kV with 100 mL of contrast material)
Trial: 21926861
Drug: Protocol A
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol A (standard 120 kV with 150 mL of contrast material)
Trial: 19194995
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 40-100 mg
Trial: 9222944
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline infusion
Trial: 16304280
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution challenge
Trial: 10598692
Drug: Dorzolamide-timolol combination
RxNorm normalized name: dorzolamide / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide-timolol combination (2.0% dorzolamide and 0.5% timolol) administered twice daily plus placebo once daily
Trial: 10598692
Drug: 2.0% Dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0% Dorzolamide administered three times daily plus placebo once daily
Trial: 10598692
Drug: 0.5% Timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% Timolol administered twice daily plus placebo once daily
Trial: 1662636
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg single dose on day 1, followed by 250 mg once-daily on days 2-5)
Trial: 1662636
Drug: Cefaclor (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (500 mg t.i.d. for 10 days)
Trial: 29433850
Drug: Lenvatinib (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg)
Trial: 29433850
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg twice-daily in 28-day cycles)
Trial: 11172833
Drug: Cetrorelix acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate 3 mg
Trial: 11899964
Drug: Cr supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr supplements as brewer's yeast
Trial: 11899964
Drug: Cr supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr supplements as CrCl3
Trial: 11899964
Drug: Cr supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr supplements (both types)
Trial: 11899964
Drug: Subjects responding
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects responding to Cr supplement
Trial: 10078403
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose mivacurium (0.08 mg.kg‐1)
Trial: 10078403
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose succinylcholine (0.5 mg.kg‐1)
Trial: 7723664
Drug: Overnight branched-chain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight branched-chain amino acid (BCAA) infusion
Trial: 21724263
Drug: Intravitreal 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal 1.25 mg/0.05 ml bevacizumab injection 1 to 14 days before PPV (Group 1)
Trial: 21724263
Drug: Intravitreal 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal 1.25 mg/0.05 ml bevacizumab injection at the end of PPV (Group 2)
Trial: 21724263
Drug: No IVB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IVB injection (Group 3)
Trial: 18173006
Drug: Lactofem (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactofem (1 capsule and 2 ml of gel every third day for one month)
Trial: 18173006
Drug: Metronidazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (1 g daily for 7 days)
Trial: 14716182
Drug: Intravaginal estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginal estriol (1 mg once daily for 2 weeks, then 2 ovules once weekly for 6 months)
Trial: 14716182
Drug: Inert placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert placebo vaginal suppositories
Trial: 9192511
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 microg twice daily)
Trial: 11549632
Drug: Calcium (500
RxNorm normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (500 mg twice daily)
Trial: 7509244
Drug: Acetorphan (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetorphan (300 mg)
Trial: 7509244
Drug: Cilazapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (5 mg)
Trial: 3044506
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 micrograms (one puff) given twice daily during 6-week treatment period
Trial: 3044506
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one puff) given twice daily during 6-week control period
Trial: 12545290
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg twice a day
Trial: 8872871
Drug: IV 0.5
RxNorm normalized name: Immphentiv 0.5 MG per 5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 0.5 mg scopolamine (SCO)
Trial: 6427609
Drug: Cimetidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (300 mg) four times daily
Trial: 31454347
Drug: Integration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integration of a preventive nutrition package including age-appropriate behavior change communication (BCC) and small-quantity lipid-based nutrient supplements (SQ-LNS)
Trial: 29548623
Drug: RUSF-v (fortified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUSF-v (fortified with arginine and citrulline, daily chloroquine 3 mg/kg)
Trial: 29548623
Drug: RUSF-b (basic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUSF-b (basic formulation, weekly chloroquine 150 mg or 225 mg)
Trial: 22762844
Drug: Edaravone 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone 20 mg
Trial: 22762844
Drug: Edaravone 30
RxNorm normalized name: edaravone 30 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone 30 mg (single dose)
Trial: 22762844
Drug: Edaravone 60
RxNorm normalized name: edaravone 60 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone 60 mg
Trial: 22762844
Drug: Edaravone 30
RxNorm normalized name: edaravone 30 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone 30 mg (repeated dosing)
Trial: 11120927
Drug: Maternal viral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal viral RNA levels >43,000 copies/mL
Trial: 9834048
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg zaleplon
Trial: 10849244
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg zolpidem
Trial: 2678768
Drug: Cefoxitin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (5 doses beginning 0.5‐1.0 hour preoperatively)
Trial: 31574343
Drug: Licorice syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licorice syrup (5 cc, twice a day for 6 months)
Trial: 31574343
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup (5 cc, twice a day for 6 months)
Trial: 30612487
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy for insomnia (CBTi)
Trial: 26924011
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding plus domperidone
Trial: 19742431
Drug: Adjunctive therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive therapies
Trial: 17617280
Drug: Amlodipine 5
RxNorm normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine 5 mg + valsartan 320 mg
Trial: 17617280
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg + valsartan 160 mg
Trial: 17617280
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg + valsartan 320 mg
Trial: 20234783
Drug: Amlodipine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine monotherapy
Trial: 12611200
Drug: Both medicines
RxNorm normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both medicines
Trial: 31764804
Drug: Integrated traditional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated traditional Chinese and Western medicine treatment group
Trial: 29077816
Drug: Chewing gum
RxNorm normalized name: Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewing gum (chlorophyll flavour, with 2.1 g carbohydrate)
Trial: 22530879
Drug: Glucose drink
RxNorm normalized name: Dextrose 15 GM Oral Solution [RELION GLUCOSE DRINK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose drink (1.0 g·kg(‐1) body weight)
Trial: 19304119
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day enalapril plus 80 mg/day valsartan (combination group)
Trial: 19304119
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day enalapril (control group)
Trial: 17805035
Drug: Alendronate (Fosamax)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (Fosamax) administered for at least 6 months
Trial: 15657405
Drug: Individualized dosing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dosing of docetaxel (mean 58.1 mg/m2, range 37.4 to 76.4 mg/m2)
Trial: 15657405
Drug: BSA-based dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSA-based dosing of docetaxel (60 mg/m2)
Trial: 15657405
Drug: Individualized dosing
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized dosing of docetaxel